Company Profile

Developing advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates, ProLynx LLC is structured around enabling long-acting delivery of small molecules, peptides and proteins. The ProLynx β-eliminative drug delivery system uses sets of novel linkers that are pre-programmed to cleave at different rates to allow the controlled, predictable and sustained release of native, active drugs—peptides, proteins and small molecules—from circulating and semi-solid macromolecular conjugates for weeks to months. The company applies its technology to extend half-lives and improve properties of the drug candidates of pharmaceutical companies as well as to enhance properties of off-patent therapeutics. A new format developed by Polyynx for releasable macromolecular-drug conjugates that does not require enzyme hydrolysis. The proprietary technology uses sets of novel linkers that undergo β-elimination reactions at different, pre-programmed rates to release native drugs – peptides, proteins and small molecules – from macromolecular co